Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) Debt Ratio (2020 - 2025)

Inhibikase Therapeutics (IKT) has 6 years of Debt Ratio data on record, last reported at 0.0 in Q2 2025.

  • On a quarterly basis, Debt Ratio fell 97.52% to 0.0 in Q2 2025 year-over-year; TTM through Jun 2025 was 0.0, a 97.52% decrease, with the full-year FY2024 number at 0.0, down 89.17% from a year prior.
  • Debt Ratio reached 0.0 in Q2 2025 per IKT's latest filing, down from 0.0 in the prior quarter.
  • Over the last five years, Debt Ratio for IKT hit a ceiling of 0.03 in Q3 2024 and a floor of 0.0 in Q2 2025.
  • A 5-year average of 0.01 and a median of 0.01 in 2022 define the central range for Debt Ratio.
  • Peak YoY movement for Debt Ratio: surged 298.06% in 2024, then tumbled 97.52% in 2025.
  • Tracing IKT's Debt Ratio over 5 years: stood at 0.01 in 2021, then increased by 15.64% to 0.01 in 2022, then soared by 76.92% to 0.01 in 2023, then crashed by 89.17% to 0.0 in 2024, then tumbled by 61.9% to 0.0 in 2025.
  • Business Quant data shows Debt Ratio for IKT at 0.0 in Q2 2025, 0.0 in Q1 2025, and 0.0 in Q4 2024.